Challenges to curing primary brain tumours

[1]  J. Gartner,et al.  Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer , 2018, Nature Medicine.

[2]  M. Oldham,et al.  A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. , 2018, Cancer cell.

[3]  A. Abbott.  Is ‘friendly fire’ in the brain provoking Alzheimer’s disease? , 2018, Nature.

[4]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[5]  F. Zipp,et al.  EGFL7 reduces CNS inflammation in mouse , 2018, Nature Communications.

[6]  Koji Ando,et al.  A molecular atlas of cell types and zonation in the brain vasculature , 2018, Nature.

[7]  Wei-Hao Liao,et al.  Focused shockwave induced blood-brain barrier opening and transfection , 2018, Scientific Reports.

[8]  M. Roussel,et al.  Establishing a Preclinical Multidisciplinary Board for Brain Tumors , 2018, Clinical Cancer Research.

[9]  N. Perrimon,et al.  Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA) , 2017, Proceedings of the National Academy of Sciences.

[10]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[11]  Steven D Chang,et al.  Single-Cell RNAseq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma , 2017, bioRxiv.

[12]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[13]  Brian M Alexander,et al.  Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE , 2017, Clinical Cancer Research.

[14]  K. Brindle,et al.  Brain Tumor Imaging. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. June,et al.  Immunotherapy for Brain Tumors. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Weller,et al.  Vaccine-based immunotherapeutic approaches to gliomas and beyond , 2017, Nature Reviews Neurology.

[17]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[18]  D. Quail,et al.  The Microenvironmental Landscape of Brain Tumors. , 2017, Cancer cell.

[19]  F. Wong,et al.  Brain Tumor Imaging , 2017, The Journal of Nuclear Medicine.

[20]  E. De Carli,et al.  [Immunotherapy in brain tumors]. , 2017, Annales de pathologie.

[21]  K. Aldape,et al.  The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants , 2016, Acta Neuropathologica.

[22]  Mariella G. Filbin,et al.  Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma , 2016, Nature.

[23]  G. Armstrong,et al.  Hypothalamic-Pituitary Axis Dysfunction in Survivors of Childhood CNS Tumors: Importance of Systematic Follow-Up and Early Endocrine Consultation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Walsh,et al.  Intellectual Outcome in Molecular Subgroups of Medulloblastoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Prehn,et al.  Advances in immunotherapy for the treatment of glioblastoma , 2016, Journal of Neuro-Oncology.

[26]  B. Geoerger,et al.  CNS tumoursThe first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas , 2016 .

[27]  T. Merchant,et al.  Long-Term Neurocognitive Functioning and Social Attainment in Adult Survivors of Pediatric CNS Tumors: Results From the St Jude Lifetime Cohort Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[29]  S. Cichon,et al.  Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma , 2016, Clinical Cancer Research.

[30]  In-Hee Lee,et al.  Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.

[31]  K. Hoang-Xuan,et al.  Clinical trial of blood-brain barrier disruption by pulsed ultrasound , 2016, Science Translational Medicine.

[32]  A. Viale,et al.  Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[34]  R. Stupp,et al.  Corticosteroids compromise survival in glioblastoma. , 2016, Brain : a journal of neurology.

[35]  A. Álvarez-Buylla,et al.  The Adult Ventricular-Subventricular Zone (V-SVZ) and Olfactory Bulb (OB) Neurogenesis. , 2016, Cold Spring Harbor perspectives in biology.

[36]  Qiulian Wu,et al.  A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. , 2016, Cancer research.

[37]  Mark L. Greenberg,et al.  Clinical and treatment factors determining long‐term outcomes for adult survivors of childhood low‐grade glioma: A population‐based study , 2016, Cancer.

[38]  M. Roussel,et al.  Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. , 2016, Cancer cell.

[39]  W. Banks,et al.  From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery , 2016, Nature Reviews Drug Discovery.

[40]  S. Razavi,et al.  Immune Evasion Strategies of Glioblastoma , 2016, Front. Surg..

[41]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[42]  Gary D. Bader,et al.  Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.

[43]  C. Stewart,et al.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature , 2016, Clinical Pharmacokinetics.

[44]  Emily J. Girard,et al.  Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. , 2015, Cell reports.

[45]  Jonathan Kipnis,et al.  Revisiting the Mechanisms of CNS Immune Privilege. , 2015, Trends in immunology.

[46]  J. Rich,et al.  Cancer stem cells in glioblastoma , 2015, Genes & development.

[47]  Traci M. Blonquist,et al.  Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  D. Ellison,et al.  An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes , 2015, Nature Genetics.

[49]  Gelareh Zadeh,et al.  Glioblastoma: pathology, molecular mechanisms and markers , 2015, Acta Neuropathologica.

[50]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[51]  M. Chintagumpala,et al.  Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss , 2015, Nature Genetics.

[52]  Christopher S. Bjornsson,et al.  It takes a village: constructing the neurogenic niche. , 2015, Developmental cell.

[53]  Malcolm A. Smith,et al.  Remaining challenges in childhood cancer and newer targeted therapeutics. , 2015, Pediatric clinics of North America.

[54]  Helmut Kettenmann,et al.  The role of microglia and macrophages in glioma maintenance and progression , 2015, Nature Neuroscience.

[55]  S. Fields,et al.  Deep mutational scanning: a new style of protein science , 2014, Nature Methods.

[56]  Gary D Bader,et al.  Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma , 2014, Nature.

[57]  J. Joyce,et al.  Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. , 2014, Immunotherapy.

[58]  Li Ding,et al.  C11ORF95-RELA FUSIONS DRIVE ONCOGENIC NF-KB SIGNALING IN EPENDYMOMA. , 2014 .

[59]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[60]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[61]  Li Ding,et al.  C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma , 2014, Nature.

[62]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[63]  Shein-Chung Chow,et al.  Adaptive clinical trial design. , 2014, Annual review of medicine.

[64]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[65]  Carmen L. Wilson,et al.  Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. , 2013, Archives of physical medicine and rehabilitation.

[66]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[67]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[68]  Gilbert Vezina,et al.  Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth following chemotherapy , 2012, Nature.

[70]  M. Giovannini,et al.  WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum , 2012, Development.

[71]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[72]  S. Scherer,et al.  Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.

[73]  J. Stockman,et al.  Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .

[74]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[75]  W. Yung,et al.  An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. , 2011, Cancer cell.

[76]  R. Gilbertson,et al.  Mapping Cancer Origins , 2011, Cell.

[77]  James B. Mitchell,et al.  Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1‐13C]pyruvate and 13C magnetic resonance spectroscopic imaging , 2011, Magnetic resonance in medicine.

[78]  B. Barres,et al.  Pericytes are required for blood–brain barrier integrity during embryogenesis , 2010, Nature.

[79]  F. Ginhoux,et al.  Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.

[80]  A. Byars,et al.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. , 2010, The New England journal of medicine.

[81]  Yiai Tong,et al.  Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.

[82]  Amar Gajjar,et al.  Cross-species genomics matches driver mutations and cell compartments to model ependymoma , 2010, Nature.

[83]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Arnold Kriegstein,et al.  The glial nature of embryonic and adult neural stem cells. , 2009, Annual review of neuroscience.

[85]  F. Turkheimer,et al.  A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. , 2009, Cancer research.

[86]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[87]  E. Gerstner,et al.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[89]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[90]  Douglas C. Miller,et al.  Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[92]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[93]  L. D.,et al.  Brain tumors , 2005, Psychiatric Quarterly.

[94]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[95]  B. Scheithauer,et al.  Microglia in brain tumors , 2002, Glia.

[96]  D. Steindler,et al.  Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro , 2002, Glia.

[97]  R. Sposto,et al.  Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. , 2001, Medical and pediatric oncology.

[98]  L. Rorke,et al.  Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  M. Scott,et al.  Altered neural cell fates and medulloblastoma in mouse patched mutants. , 1997, Science.

[100]  G. Reaman,et al.  Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. , 1996, Blood.

[101]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[102]  M E Cohen,et al.  Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. , 1993, The New England journal of medicine.

[103]  S. Segawa,et al.  End of the beginning , 1990, Nature.

[104]  J. Sneep,et al.  With a summary , 1945 .